AIRNA
Cambridge
About AIRNA
AIRNA focuses on RNA editing technologies to develop innovative medicines aimed at treating various diseases. The company engages in research and development to create therapeutic solutions that target genetic disorders, offering potential functional cures. Airna's approach involves utilizing advanced RNA editing techniques to repair or modify genetic sequences, thereby addressing both rare and common health conditions. The team is committed to scientific collaboration and innovation, striving to enhance patient outcomes through their work in biotechnology. By leveraging cutting-edge methodologies, Airna contributes to the evolving landscape of genetic medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $245.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2025)
- Website: airna.com
- Phone: 6179357092
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/airna-25439 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.